Nexium and Prilosec are proton pump inhibitors (PPIs) that are used to decrease the amount of acid produced in the stomach.
Proton pump inhibitors are commonly used to treat gastroesophagal reflux disease (GERD) and peptic ulcer disease (PUD). Prilosec, originally approved as Losec in 1988, was the first member of the Proton Pump Inhibitor class of medications. Nexium is a second generation proton pump inhibitor said to be an improvement on Prilosec. Both are manufactured by AstraZeneca.
A February, 2016 issue of the Journal of the American Medical Association (JAMA), published the results of a new study which showed a higher risk of chronic kidney disease in patients using proton pump inhibitors like Nexium (esomeprazole), Prilosec (omeprazole), and similar prescription and over-the-counter medications. The results showed the risk of chronic kidney disease was higher with prolonged use.
Moll Law Group has been contacted by a large number of PPI users around the country and is currently investigating the filing of lawsuits for claims of acute interstitial nephritis, chronic kidney disease, and renal or kidney failure.
"A team of lawyers from around the country are reviewing numerous claims of kidney damage from users of proton pump inhibitors. We are conducting free reviews for anyone who had any type of kidney injury following use of proton pump inhibitors (Nexium, Prilosec, Prevacid, Protonix, etc.)," stated Attorney Ken Moll, President of Moll Law Group.
About Moll Law Group
Moll Law Group is a national injury law firm based in Chicago helping injured victims obtain the compensation they deserve.
For a copy of the Complaint click here - - > http://www.molllawgroup.com/proton-pump-inhibitors.html
Logo - http://photos.prnewswire.com/prnh/20160415/356156LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chicago-law-firm-files-first-lawsuit-against-astrazeneca-on-behalf-of-tennessee-man-who-suffered-serious-and-permanent-life-threatening-injuries-following-his-use-of-nexium-300293975.html
SOURCE Moll Law Group